MedTrace Logo

The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency

NCT01598337 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2012-05-15

No results posted yet for this study

Summary

This protocol is designed to evaluate the effect of antiplatelets (Tirafiban and Prasugrel) on the incidence of early and intermediate graft patency after CABG.

Conditions

Interventions

DRUG

Aspirin

Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily

DRUG

Tirofiban

Tirofiban infusion as specified by investigators to start after hemostasis been established

DRUG

Clopidogrel

75 mg orally started 6-8hours before surgery

DRUG

Prasugrel

10 mg daily as per instructions of investigators

Sponsors & Collaborators

  • Prince Sultan Cardiac Center, Adult Cardiology Department.

    lead OTHER

Principal Investigators

  • Hussein S Al-Amri, MD · Prince Sultan Cardiac Center (PSCC), Riyadh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-12-31

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01598337 on ClinicalTrials.gov